A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advance Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 May 2017
At a glance
- Drugs RG 6061 (Primary)
- Indications Liver metastases; Solid tumours
- Focus Biomarker; Pharmacodynamics
- 01 Feb 2014 Status changed from completed to discontinued according to results published in the Cancer Chemotherapy and Pharmacology.
- 01 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.